Stocklytics Platform
Asset logo for symbol NRIX
Nurix Therapeutics
NRIX64
$19.57arrow_drop_down2.22%-$0.44
Asset logo for symbol NRIX
NRIX64

$19.57

arrow_drop_down2.22%

Income Statement (NRIX)

itemAug 2024May 2024Feb 2024Nov 2023Aug 2023
EBIT-$54.61M-$48.54M-$45.21M-$45.33M-$40.01M
EBITDA-$50.46M-$44.44M-$41.33M-$41.57M-$36.62M
gross Profit$8.44M$8.00M$12.69M$11.40M$15.08M
NET Income-$48.95M-$44.54M-$41.51M-$41.95M-$36.98M
total Revenue$12.58M$12.09M$16.58M$15.15M$18.46M

Balance Sheet (NRIX)

itemAug 2024May 2024Feb 2024Nov 2023Aug 2023
cash Equivalents-----
net Debt-$71.90M-$87.97M-$20.65M-$24.01M-$34.30M
stockholders Equity$376.85M$370.69M$168.74M$200.49M$233.81M
total Assets$513.60M$511.03M$312.67M$364.53M$308.19M
total Debt$27.14M$28.81M$29.15M$30.61M$8.00M
total Liabilities$136.74M$140.33M$143.92M$164.04M$74.37M

Cash Flow (NRIX)

itemAug 2024May 2024Feb 2024Nov 2023Aug 2023
financing Cash Flow$45.77M$237.75M$1.62M$4.94M$1.70M
free Cash Flow-$44.52M-$41.64M-$44.83M$19.16M-$43.59M
investing Cash Flow----$22.77M
operating Cash Flow-$42.17M-$39.70M-$41.95M$21.74M-$41.13M

Nurix Therapeutics (NRIX) Financials

Nurix Therapeutics, Inc. (NRIX) is a biopharmaceutical company that focuses on the discovery and development of small molecule therapies to modulate protein levels and protein degradation. A key component of understanding the financial health of Nurix Therapeutics, Inc. is analyzing its income statement. The income statement provides an overview of the company's revenues, expenses, and profits over a specific period. By examining the income statement, investors can gain insights into the company's profitability. For Nurix Therapeutics, Inc., it is important to analyze the company's gross profit, EBIT (Earnings Before Interest and Taxes), and net income from stockholders. These financial metrics provide a holistic view of the company's financial performance.
One of the key metrics used to evaluate Nurix Therapeutics, Inc.'s financial health is EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization). EBITDA provides a clearer picture of the company's operating performance by excluding non-operating expenses such as interest and taxes. In addition to EBITDA, it is also important to analyze the company's total revenue, which represents the total amount of money generated from the sale of goods or services. This metric indicates the company's overall sales performance. By examining the balance sheet, investors can gain insights into Nurix Therapeutics, Inc.'s financial position. Key components of the balance sheet include cash equivalents, net debt, stockholders' equity, total assets, total debt, and total liabilities. These metrics provide a snapshot of the company's financial standing at a specific point in time.
When evaluating Nurix Therapeutics, Inc.'s cash flow, investors should examine the company's operating cash flow, investing cash flow, and financing cash flow. Operating cash flow represents the amount of cash generated by the company's core business operations. Investing cash flow reflects cash flows related to investments in fixed assets or acquisitions. Financing cash flow represents cash flows related to the company's financing activities, such as the issuance of debt or equity. By analyzing these cash flow metrics, investors can assess the company's ability to generate and manage cash. Additionally, free cash flow, which is calculated by subtracting capital expenditures from operating cash flow, provides insights into the company's ability to generate excess cash for reinvestment or distribution to shareholders.
add Nurix Therapeutics to watchlist

Keep an eye on Nurix Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Take Your Investments to a Whole New Level